Page 54 - Characterization of genetic neurodevelopmental disorders at adult age, with a focus on 22q11.2 deletion syndrome - Emma Boersma

Chapter 2
38. Yasa S, Modica G, Sauvageau E, Kaleem A, Hermey G, Lefrancois S. CLN3 regulates
endosomal function by modulating Rab7A-effector interactions. J Cell Sci. Mar 16 2020;133(6)
doi:10.1242/jcs.234047
39. Schweizer M, Markmann S, Braulke T, Kollmann K. Ultrastructural analysis of neuronal and
non-neuronal lysosomal storage in mucolipidosis type II knock-in mice. Ultrastruct Pathol. Oct
2013;37(5):366-72. doi:10.3109/01913123.2013.810687
40. Yu SH, Wang T, Wiggins K, et al. Lysosomal cholesterol accumulation contributes to the
movement phenotypes associated with NUS1 haploinsufficiency. Genet Med. Mar 17
2021;doi:10.1038/s41436-021-01137-6
41. Tang BL. Rabs, Membrane Dynamics, and Parkinson’s Disease. J Cell Physiol. Jul
2017;232(7):1626-1633. doi:10.1002/jcp.25713
42. Koss DJ, Campesan S, Giorgini F, Outeiro TF. Dysfunction of RAB39B-Mediated Vesicular
Trafficking in Lewy Body Diseases. Mov Disord. May 3 2021;doi:10.1002/mds.28605
43. Renvoisé B, Chang J, Singh R, et al. Lysosomal abnormalities in hereditary spastic paraplegia
types SPG15 and SPG11. Ann Clin Transl Neurol. Jun 1 2014;1(6):379-389. doi:10.1002/acn3.64
44. Pozner T, Regensburger M, Engelhorn T, Winkler J, Winner B. Janus-faced spatacsin (SPG11):
involvement in neurodevelopment and multisystem neurodegeneration. Brain. Aug 1
2020;143(8):2369-2379. doi:10.1093/brain/awaa099
45. Fernandes Filho JA, Shapiro BE. Tay-Sachs disease. Arch Neurol. Sep 2004;61(9):1466-8.
doi:10.1001/archneur.61.9.1466
46. Dubos A, Castells-Nobau A, Meziane H, et al. Conditional depletion of intellectual disability and
Parkinsonism candidate gene ATP6AP2 in fly and mouse induces cognitive impairment and
neurodegeneration. Hum Mol Genet. Dec 1 2015;24(23):6736-55. doi:10.1093/hmg/ddv380
47. Desplats P, Patel P, Kosberg K, et al. Combined exposure to Maneb and Paraquat alters
transcriptional regulation of neurogenesis-related genes in mice models of Parkinson’s
disease. Mol Neurodegener. Sep 28 2012;7:49. doi:10.1186/1750-1326-7-49
48. Fan SP, Lee NC, Lin CH. Novel Phenotype of 6p25 Deletion Syndrome Presenting Juvenile
Parkinsonism and Brain Calcification. Mov Disord. May 5 2020;doi:10.1002/mds.28079
49. Porta F, Mussa A, Concolino D, Spada M, Ponzone A. Dopamine agonists in dihydropteridine
reductase deficiency. Mol Genet Metab. Apr 2012;105(4):582-4. doi:10.1016/j.
ymgme.2012.01.013
50. Bouchereau J, Huttlin EL, Guarani V, Pichard S, Anikster Y, Schiff M. DNAJC12: A molecular
chaperone involved in proteostasis, PKU, biogenic amines metabolism and beyond? Mol Genet
Metab. Mar 2018;123(3):285-286. doi:10.1016/j.ymgme.2018.01.006
51. Ng J, Barral S, De La Fuente Barrigon C, et al. Gene therapy restores dopamine transporter
expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.
Sci Transl Med. May 19 2021;13(594)doi:10.1126/scitranslmed.aaw1564
52. Catterall WA. Dravet Syndrome: A Sodium Channel Interneuronopathy. Curr Opin Physiol. Apr
2018;2:42-50. doi:10.1016/j.cophys.2017.12.007
53. Tassin J, Durr A, Bonnet AM, et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or
parkin mutations? Brain. Jun 2000;123 ( Pt 6):1112-21. doi:10.1093/brain/123.6.1112
54. Bergoug M, Doudeau M, Godin F, Mosrin C, Vallée B, Bénédetti H. Neurofibromin Structure,
Functions and Regulation. Cells. Oct 27 2020;9(11)doi:10.3390/cells9112365
55. Curtius HC, Niederwieser A, Viscontini M, et al. Serotonin and dopamine synthesis in
phenylketonuria. Adv Exp Med Biol. 1981;133:277-91. doi:10.1007/978-1-4684-3860-4_16
56. Boot E, Hollak CEM, Huijbregts SCJ, et al. Cerebral dopamine deficiency, plasma monoamine
alterations and neurocognitive deficits in adults with phenylketonuria. Psychol Med. Dec
2017;47(16):2854-2865. doi:10.1017/s0033291717001398
57. Hetzelt K, Kerling F, Kraus C, et al. Early-onset parkinsonism in PPP2R5D-related
neurodevelopmental disorder. Eur J Med Genet. Jan 2021;64(1):104123. doi:10.1016/j.
ejmg.2020.104123
58. Peng XM, Tehranian R, Dietrich P, Stefanis L, Perez RG. α-Synuclein activation of protein
phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. Journal
of Cell Science. 2005;118(15):3523-3530. doi:10.1242/jcs.02481
52